D.A. Davidson & Co. Seagen Inc. Transaction History

D.A. Davidson & Co.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$191.51 - $216.16 $17,618 - $19,886	-92 Reduced 3.09%	2,881 $611,000
Q2 2023 Aug 10, 2023	SELL	$187.64 - $206.25 $20,828 - $22,893	-111 Reduced 3.6%	2,973 $572,000
Q1 2023 Apr 25, 2023	SELL	$127.59 - $203.08 $44,784 - $71,281	-351 Reduced 10.22%	3,084 $624,000
Q4 2022 Feb 03, 2023	BUY	$117.37 - $139.17 $2,699 - $3,200	23 Added 0.67%	3,435 $441,000
Q3 2022 Nov 07, 2022	SELL	$135.27 - $180.11 $2,840 - $3,782	-21 Reduced 0.61%	3,412 $467,000
Q2 2022 Jul 28, 2022	SELL	$108.81 - $179.33 $49,508 - $81,595	-455 Reduced 11.7%	3,433 $607,000
Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $119,370 - $157,534	-998 Reduced 20.43%	3,888 $560,000
Q4 2021 Jan 31, 2022	SELL	$142.57 - $190.86 $11,405 - $15,268	-80 Reduced 1.61%	4,886 $755,000
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $13,105 - $15,623	92 Added 1.89%	4,966 $843,000
Q2 2021 Aug 10, 2021	BUY	$135.08 - $161.1 $50,925 - $60,734	377 Added 8.38%	4,874 $770,000
Q1 2021 May 07, 2021	BUY	$137.51 - $190.8 $69,167 - $95,972	503 Added 12.59%	4,497 $624,000
Q4 2020 Feb 10, 2021	BUY	$164.63 - $211.93 $657,532 - $846,448	3,994 New	3,994 $700,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.